BioNexus Gene Lab Overview
Latest P/E ratio for BioNexus Gene Lab: -1.23 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-1.23
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, BGLC shows a P/E ratio of -1.23. That is below the sector sector average of 33.83. Scroll down for historical charts and peer comparison views.
The its sector sector average P/E ratio is about 33.83. BioNexus Gene Lab is at -1.23, which is lower that average. That is roughly 103.6% below the sector mean. Use the comparison chart on this page to see how BGLC stacks up against individual peers as well.
Investors watch BGLC's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. BioNexus Gene Lab's latest reading is -1.23. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has BioNexus Gene Lab's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -1.23) with ownership activity and broader fundamentals.
